SEC probes SAC Capital over profits from biotech buyout; Bernstein gives slim odds to Abbott business attracting bids;

@FierceBiotech: Eyetech vets launch Imagen Biotech with $40M A round. Will work on new treatments for dry AMD, other eye diseases. News | Follow @FierceBiotech

@JohnCFierce: Development stage biotech IRX is moving to FL, where it promises to grow from 40 to 280 in 5 yrs. What are the odds? Item | Follow @JohnCFierce

@RyanMFierce: Full BG-12 data from DEFINE this AM, still looks promising, still waiting for CONFIRM results. Report | Follow @RyanMFierce

@MaureenFierce: MIT tech could boost AIDS vaccine work. Story | Follow @MaureenFierce

> SAC Capital Advisors is under investigation as SEC officials seek to determine whether the hedge fund profited illegally on Johnson & Johnson's ($JNJ) buyout of cancer drug developer Cougar Biotechnology in 2009. Article

> Sanford C. Bernstein analysts gave slim odds of a pharma company bidding on Abbott Labs' drug business amid Abbott's recent plans to split into two companies. Report

> Halozyme Therapeutics ($HALO) reported upbeat data from a Phase II trial of a fast-acting insulin formulation for diabetics. Release

> The FDA approved Watson Pharmaceuticals' ($WPI) its Androderm product, which is a patch that delivers testosterone through the skin. Item

> Merck ($MRK) said that its recently approved HepC drug Victrelis performed well in a clinical trial as a treatment for HIV. Report

Pharma News

@FiercePharma: Report: Abbott prescription med unit could bring $54M. News | Follow @FiercePharma

> EC investigates J&J, Novartis over generic Fentanyl delay. Story

> Schwan: Roche to pursue 'targeted acquisitions'. Article

> Merck to make new investments in Singapore. More

> AMAG stockholders vote against merger with Allos. Story

> Australian officials seek more info on Pfizer support program. Piece

> Actavis loses oxycodone, epilepsy meds in cargo theft. Report

And Finally... The British Medical Journal published research that provides more evidence that mobile phone use doesn't cause brain cancer. Article

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.